Company intelligence / Profile preview

CytoSwim

Coventry, England, United Kingdomcytoswim.com ↗

Ownership: Private
Development stage: Commercial

Overview

CytoSwim has developed the patented SpermAlign microstructure platform, which uses biomimetic design to select the healthiest sperm cells by guiding them through a thigmotaxis-based "obstacle course." This field-free separation reduces DNA fragmentation risk up to 10x compared to conventional methods. The device aims to improve ART outcomes by providing higher-quality sperm for IVF and related procedures[1][2].

Therapeutic areas: Women's HealthMen's Health
Modalities: DeviceNon-pharmacological therapy (sperm selection tool)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SpermAlign

Commercial

Indications: Infertility

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on CytoSwim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoSwim.

Explore the full profile